Karger Publishers
Supplementary material-Supplementary_Material.docx (20.88 kB)

Supplementary Material for: Smartwatch ECG tracing and ischemic heart disease. ACS Watch Study

Download (20.88 kB)
posted on 2022-11-21, 08:22 authored by BuelgaSuárez M., PascualIzco M., PastorPueyo P., LozanoGranero V., GarcíaMontalvo J., AlonsoSalinas G.L.
BACKGROUND Smartwatches have become a widely used tool for health self-care. Its role in ischemic heart disease (IHD) has not been assessed. OBJETCIVES To evaluate the usefulness of smartwatch ECG registry in IHD. METHODS We present an observational study of 25 consecutive patients with acute IHD. Conventional ECG and smartwatch tracing were obtained simultaneously at admission. Waves of conventional and smartwatch ECGs were objectively compared. A survey on medical attitude was conducted among 12 physicians (3 cardiologists, 3 intensivists, 3 emergency physicians, and 3 general practitioners) and a score (1 to 5) of concordance between the records was requested. RESULTS There were no differences in Q wave, R wave, ST segment, or T wave. There was a very strong correlation between ST segments, a strong correlation in Q waves and R waves, and a moderate correlation in T wave measurements. All specialists obtained a high level of agreement (4.45±0.45). Smartwatch tracings would lead to similar management compared to conventional ECG. There were only 6 (2%) discrepant cases due to differences in inferior repolarization, showing an almost perfect agreement (kappa=0.96). CONCLUSIONS In most patients with acute IHD, smartwatch ECG tracing is a reliable tool to make the diagnosis and guide appropriate medical care. However, due to their intrinsic limitations, inferior myocardial infarctions may be missed and require a conventional 12-lead ECG to rule them out.


Usage metrics